Zoetis receives FDA approval for dog treatment: what it means for Zoetis stock

Published on 10/25/2026 at 13:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zoetis received FDA approval for a 14-day dog treatment on October 20, 2026. Zoetis stock has Q3 results on November 5, 2026.

Approval and earnings dates

Zoetis received FDA approval for Convenia RTU on October 20, 2026, with a 14-day treatment duration.
Second-quarter 2026 revenue was USD 2.47 billion, while net income reached USD 691.0 million.
Zoetis stock closed at EUR 72.40 on Xetra on October 23, 2026.
Zoetis is scheduled to report third-quarter results on November 5, 2026.

ZTS, US98978V1035, Illustration mit AI erstellt.

Zoetis Inc. (US98978V1035) received U.S. Food and Drug Administration approval on October 20, 2026, for Convenia RTU for Dogs, an injectable treatment that can provide up to 14 days of antibiotic therapy. The company is scheduled to report third-quarter results on November 5, 2026.

FDA approval adds a product milestone

According to Zoetis, Convenia RTU is intended for susceptible bacterial skin infections in dogs and is administered by a veterinary professional. The company expects the product to become available to veterinarians in the first quarter of 2027.

What does 14 days mean for investors?

The treatment extends the company's companion-animal product offering with a single-injection format for dogs of all sizes. That commercial angle matters as pricing power has become a central concern for the stock.

On October 20, 2026, Jefferies downgraded Zoetis to Hold from Buy and cut its price target from USD 103 to USD 83, a 19.42 percent reduction, according to Markets Insider. The firm cited a softer pricing environment and limited visibility on future margin expansion.

Three dated Zoetis developments

Zoetis declared a fourth-quarter 2026 dividend of USD 0.53 per share on October 8, 2026, according to Business Wire. It appointed Iris Knobloch to its board effective December 1, 2026, on October 13, 2026, as reported by Business Wire. The October 20 FDA approval is the latest of the three events.

Two dates shape the next steps

The dividend record and ex-dividend date is October 30, 2026, while the next quarterly report is scheduled for November 5, 2026. The earnings date is listed by Yahoo Finance.

Second-quarter results set the baseline

Zoetis reported USD 2.47 billion in revenue and USD 691.0 million in net income for the second quarter of 2026, with revenue down 0.20 percent year over year, according to Yahoo Finance. The figures give investors a recent operating benchmark before the November report.